Randomized trial demonstrates safety and efficacy of PSB202 in relapsed or refractory B-cell malignancies, suggesting a new treatment approach.
Key Points
This trial aims to evaluate the safety and efficacy of PSB202, a bifunctional antibody targeting CD20 and CD37 in relapsed or refractory B-cell malignancies.
Multicenter, open-label phase Ia trial (NCT05003141)
Adults with relapsed or refractory CD20+ B-cell non-Hodgkin lymphoma received PSB202 in escalating doses from 12 to 300 mg
Primary endpoints included dose-limiting toxicities and maximum tolerated dose.
One dose-limiting toxicity of grade 4 neutropenia occurred at 100 mg
Overall response rate was 30% in evaluable patients, including one complete response at 300 mg
PSB202 led to sustained B-cell depletion and induced IFN-γ release without cytokine release syndrome.